申请人:Li Lianfa
公开号:US08481545B2
公开(公告)日:2013-07-09
Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
提供了作为CCR1受体的强效拮抗剂的化合物,并具有体内的抗炎活性。这些化合物是3-咪唑基吡唑并[3,4-b]吡啶衍生物,可用于制药组合物、治疗CCR1介导的疾病的方法,以及作为竞争性CCR1拮抗剂鉴定试验中的对照物。